Logo image of DME.CA

DESERT MOUNTAIN ENERGY CORP (DME.CA) Stock Fundamental Analysis

TSX-V:DME - CA25043D1078 - Common Stock

0.175 CAD
0 (0%)
Last: 9/4/2025, 7:00:00 PM
Fundamental Rating

3

DME gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 803 industry peers in the Metals & Mining industry. The financial health of DME is average, but there are quite some concerns on its profitability. DME has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DME has reported negative net income.
DME had a negative operating cash flow in the past year.
In the past 5 years DME always reported negative net income.
In the past 5 years DME always reported negative operating cash flow.
DME.CA Yearly Net Income VS EBIT VS OCF VS FCFDME.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of DME (-8.69%) is better than 62.76% of its industry peers.
Looking at the Return On Equity, with a value of -9.30%, DME is in the better half of the industry, outperforming 65.75% of the companies in the same industry.
Industry RankSector Rank
ROA -8.69%
ROE -9.3%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DME.CA Yearly ROA, ROE, ROICDME.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DME.CA Yearly Profit, Operating, Gross MarginsDME.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

6

2. Health

2.1 Basic Checks

DME does not have a ROIC to compare to the WACC, probably because it is not profitable.
DME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DME.CA Yearly Shares OutstandingDME.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
DME.CA Yearly Total Debt VS Total AssetsDME.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of 1.13, we must say that DME is in the distress zone and has some risk of bankruptcy.
DME has a Altman-Z score of 1.13. This is comparable to the rest of the industry: DME outperforms 47.32% of its industry peers.
DME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.13
ROIC/WACCN/A
WACC9.43%
DME.CA Yearly LT Debt VS Equity VS FCFDME.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 2.27 indicates that DME has no problem at all paying its short term obligations.
DME has a Current ratio of 2.27. This is comparable to the rest of the industry: DME outperforms 56.04% of its industry peers.
A Quick Ratio of 2.27 indicates that DME has no problem at all paying its short term obligations.
The Quick ratio of DME (2.27) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 2.27
DME.CA Yearly Current Assets VS Current LiabilitesDME.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.08% over the past year.
DME shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -50.66%.
EPS 1Y (TTM)63.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-50.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-3.05%

3.2 Future

Based on estimates for the next years, DME will show a very strong growth in Earnings Per Share. The EPS will grow by 73.21% on average per year.
The Revenue is expected to grow by 256.37% on average over the next years. This is a very strong growth
EPS Next Y60%
EPS Next 2Y73.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year310%
Revenue Next 2Y256.37%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

DME.CA Yearly Revenue VS EstimatesDME.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
DME.CA Yearly EPS VS EstimatesDME.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 0 0.02 -0.02 0.04 -0.04 -0.06

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DME. In the last year negative earnings were reported.
DME is valuated cheaply with a Price/Forward Earnings ratio of 3.40.
Based on the Price/Forward Earnings ratio, DME is valued cheaper than 98.01% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.63, DME is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 3.4
DME.CA Price Earnings VS Forward Price EarningsDME.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DME.CA Per share dataDME.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4 0.5

4.3 Compensation for Growth

DME's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DME's earnings are expected to grow with 73.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y73.21%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DME!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DESERT MOUNTAIN ENERGY CORP

TSX-V:DME (9/4/2025, 7:00:00 PM)

0.175

0 (0%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)08-21 2025-08-21
Earnings (Next)02-02 2026-02-02
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.73%
Ins Owner ChangeN/A
Market Cap16.48M
Analysts84.44
Price Target0.51 (191.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.4
P/S 19.16
P/FCF N/A
P/OCF N/A
P/B 0.33
P/tB 0.33
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)0.05
Fwd EY29.43%
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.01
BVpS0.52
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.69%
ROE -9.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1982.72%
Cap/Sales 277.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 2.27
Altman-Z 1.13
F-Score3
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)5568.56%
Cap/Depr(5y)38613%
Cap/Sales(3y)1760.59%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y60%
EPS Next 2Y73.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-50.66%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-3.05%
Revenue Next Year310%
Revenue Next 2Y256.37%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year84.3%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y78.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.22%
OCF growth 3YN/A
OCF growth 5YN/A